paroxetine

(redirected from Paroxetine mesylate)
Also found in: Dictionary.
Related to Paroxetine mesylate: Paxil

paroxetine

 [pah-rok´sĕ-tēn]
a selective serotonin reuptake inhibitor administered orally as the hydrochloride salt as an antidepressant and to treat obsessive-compulsive, panic, and social anxiety disorders.

paroxetine

/par·ox·e·tine/ (pah-rok´sĕ-tēn) a selective serotonin uptake inhibitor used as the hydrochloride salt to treat depression and obsessive-compulsive, panic, and social anxiety disorders.

paroxetine

(pă-rŏk′sĭ-tēn′)
n.
A drug of the SSRI class, C19H20FNO3, used in its hydrochloride form to treat depression, anxiety, and certain other disorders, including obsessive-compulsive disorder.

paroxetine

a selective serotonin reuptake inhibitor.
indications It is prescribed in the treatment of mental depression, obsessive-compulsive disorder, panic disorders, and anxiety disorders, including social anxiety and general anxiety. Unlabeled uses include treatment of impulse control disorders, premenstrual syndrome, and vasomotor symptoms of menopause.
contraindications It should not be given to patients taking monoamine oxidase inhibitors. Caution is advised in administering the drug to patients with a history of drug abuse, mania, seizures, suicidal tendencies, or kidney or liver disease.
adverse effects The side effects most often reported include decreased libido and ejaculatory disturbances, nausea, diarrhea, vomiting, constipation, abdominal pain, flatulence, changes in appetite, and muscle weakness. Paroxetine may also cause SIADH and/or hyponatremia and lead to or exacerbate coagulation disturbances because of impairment of platelet aggregation.

paroxetine

A SEROTONIN RE-UPTAKE INHIBITOR drug. A brand name is Seroxat.
References in periodicals archive ?
Paroxetine mesylate, first approved in 2003 and marketed as Pexeva, is approved for major depressive disorder, obsessive compulsive disorder, panic disorder, and generalized anxiety.
Data supporting the efficacy of paroxetine mesylate are available from two studies involving 1,184 menopausal women with vasomotor symptoms randomly assigned to receive paroxetine 7.